Crohn's Disease Therapeutics Market Size, Trends, and Key Insights

The Crohn's Disease Therapeutics Market was valued at USD 4.25 billion in 2024 and is projected to grow from USD 4.34 billion in 2025 to reach USD 5.13 billion by 2033, at a CAGR of 2.1% between 2025 and 2033. North America leads the global market and is expected to grow at a CAGR of 10.50%, making it the largest stakeholder during the forecast period.

👉 Download Sample Report

Crohn's Disease, also known as regional enteritis, is a chronic inflammatory bowel disease (IBD) that causes inflammation in the digestive tract, particularly in the small and large intestines. There are four main types of Crohn's Disease: ileocolitis, ileitis, gastroduodenal, and jejunoileitis. The increasing prevalence of this condition has encouraged pharmaceutical companies to collaborate with regulatory bodies and research organizations to bring forward advanced treatments.

Market Growth Drivers
One of the major growth factors is the growing adoption of biologics, such as anti-TNF, anti-interleukin, and anti-integrin antibodies. These therapies are effective for patients resistant to traditional steroids and aminosalicylates. New biologics like ustekinumab (Stelara) and upcoming interleukin inhibitors are gaining momentum due to better clinical outcomes and easier dosing. Another driver is the successive launch of new therapies, with key biologics like Humira, Remicade, Cimzia, Entyvio, and Tysabri fueling the market alongside strong contributions from top pharmaceutical players.

Market Restraints
A key challenge for this market is the high failure rate of clinical trials. Companies like Takeda and Pfizer have terminated late-stage clinical programs for Crohn’s treatments due to funding shifts and strategy changes. Additionally, corticosteroids, though effective in remission, are unsuitable for long-term therapy because of side effects and growing generic competition.

Market Opportunities
The pipeline is strong, with high investment in R&D and the development of novel therapies such as S1P receptor modulators and stem cell-based solutions. Major players are focusing on acquisitions, partnerships, and regional expansions to gain a competitive edge. Government and industry funding in healthcare infrastructure and innovation are also expected to boost opportunities worldwide.

Regional Insights

• North America: Dominates the global market, driven by rising disease prevalence, strong healthcare initiatives, and the presence of leading pharma players.

• Europe: Expected to grow at a CAGR of 11.24%, with the UK leading due to advanced healthcare infrastructure and favorable reimbursement policies.

• Asia-Pacific: Japan is the fastest-growing market, with new therapies like Janus kinase inhibitors and upcoming launches such as Gilead’s Filgotinib driving growth.

• Middle East, Africa, and Latin America: Emerging opportunities fueled by expanding access to healthcare and increasing patient awareness.

Drug Class Insights
The TNF-Alpha inhibitors segment holds the largest share and is forecasted to grow at a CAGR of 10.29%. With the launch of new biologics such as risankizumab (Skyrizi), the market is shifting toward more effective therapies with improved safety profiles.

Gender and Age Insights

• The women’s segment dominates with a CAGR of 10.76%, as Crohn’s symptoms in women often differ and may include gynecological complications.

• By age, the 49 years and below group holds the highest share, as the disease is most commonly diagnosed between ages 20 and 30.

Disease Type Insights
The small/large-intestinal type segment contributes the most, growing at a CAGR of 10.33%, as the ileum and colon are the most affected regions.

Key Players in the Crohn's Disease Therapeutics Market

• AbbVie Inc.

• Biogen

• Takeda

• Janssen Biotech Inc. (Johnson & Johnson)

• Bristol-Myers Squibb

• AstraZeneca

• Pfizer

• Red Hill Pharma

• 4D Pharma

Recent Development
In December 2022, Pfizer Inc. announced that the FDA accepted its New Drug Application for Etrasimod in patients with moderately to severely active ulcerative colitis, with a decision expected in 2023. The European Medicines Agency also accepted its application, with results anticipated in 2024.

About Us:

Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:

Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/